Evidence map›Paper›PMID 31296907›Full record

Observational studyScientific reports2019

Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema.

Edoardo Midena, Alessandra Micera, Luisa Frizziero, Elisabetta Pilotto, Graziana Esposito, Silvia Bini

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Review
  19. Diabetic macular edema treatment with subthreshold micropulse laser - five-year long monitoring.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Edoardo MidenaDepartment of Ophthalmology, University of Padova, Padova, Italy. edoardo.midena@unipd.it.
Alessandra MiceraIRCCS - Fondazione Bietti, Rome, Italy.ORCID http://orcid.org/0000-0002-9375-6071
Luisa FrizzieroIRCCS - Fondazione Bietti, Rome, Italy.
Elisabetta PilottoDepartment of Ophthalmology, University of Padova, Padova, Italy.
Graziana EspositoIRCCS - Fondazione Bietti, Rome, Italy.
Silvia BiniIRCCS - Fondazione Bietti, Rome, Italy.
Fondazione G.B. Bietti · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subthreshold micropulse laser (SMPL) is a tissue-sparing technique whose efficacy is demonstrated for diabetic macular edema (DME) treatment. However, its mechanism of action is poorly known. A prospective observational study was performed on naïve DME patients treated with SMPL, to evaluate the changes of aqueous humor (AH) inflammatory and vaso-active biomarkers after treatments. AH samples of eighteen DME eyes were collected before and after SMPL. Ten non-diabetic AH samples served as controls. Full ophthalmic evaluation, spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography were performed in DME group. Glass chip protein array was used to quantify 58 inflammatory molecules. Central retinal thickness (CRT) and visual acuity were also monitored. Several molecules showed different concentrations in DME eyes versus controls (p value < 0.05). Fas Ligand (FasL), Macrophage Inflammatory Proteins (MIP)-1α, Regulated on Activation Normal T Cell Expressed and Secreted (RANTES) and Vascular Endothelial Growth Factor (VEGF) were increased in DME at baseline versus controls and decreased after SMPL treatments (p < 0.05). CRT reduction and visual acuity improvement were also found. Inflammatory cytokines, mainly produced by the retinal microglia, were significantly reduced after treatments, suggesting that SMPL may act by de-activating microglial cells, and reducing local inflammatory diabetes-related response.

Indexed as

Adaptor Proteins, Signal TransducingAgedAqueous HumorBlood-Retinal BarrierChemokine CCL5CytokinesDiabetes ComplicationsDiabetes MellitusDiabetic RetinopathyFas Ligand ProteinFemaleFluorescein AngiographyHumansLaser CoagulationMacular EdemaMaleAdaptor Proteins, Signal TransducingCCL5 protein, humanChemokine CCL5CytokinesFASLG protein, humanFas Ligand ProteinMAPKAP1 protein, humanVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID31296907
PMCPMC6624368
OpenAlexW2961110886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.